The UK BioIndustry Association (BIA) and the Medicines and Healthcare products Regulatory Agency (MHRA) brought together experts from across the sector to discuss some hot topics and important developments that are having an impact on the changing and dynamic UK life sciences ecosystem.
Responding to a House of Lords inquiry on life sciences and the industrial strategy, the BioIndustry Association has published new data which reveals that the majority of health care professionals are not aware of the Accelerated Access Review or previous government-led initiatives aimed at improving the adoption of innovation across the NHS.
The BIA and ABPI have welcomed the UK Government’s latest Brexit position paper on ‘Collaboration on science and innovation’. The UK Government’s position follows a prolonged effort from the life sciences industry to establish Government consensus on key Brexit issues.
The Medicines Manufacturing Industry Partnership (MMIP) has welcomed the publication of the Life Sciences Industrial Strategy, led by Sir John Bell and supported by the sector and presented today to Government.
The BioIndustry Association (BIA) welcomes the publication of the Life Sciences Industrial Strategy. Professor Sir John Bell, Regius Professor of Medicine at Oxford, has led the development of this report to government, with input from across the life sciences ecosystem, including the Life Sciences Industrial Strategy Board.
A new report published today by the Medicines Manufacturing Industry Partnership (MMIP) has asked the Government for support in creating three new Centres of Excellence for medicines manufacturing across the UK. The centres would create high-skilled jobs and make the UK the first place in the world where the next generation of medicines can be discovered, made and packaged.
A group of innovative bioscience companies that specialise in treatments for rare and very rare diseases have come together, under the umbrella of the BioIndustry Association (BIA), to form the BIA Rare Disease Industry Group (RDIG). The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and very rare conditions, sometimes referred to as orphan and ultra-orphan medicines.